SKLB-1028

• CAT Number: I009514
• CAS Number: 1350544-93-2
• Molecular Formula: C24H29N9
• Molecular Weight: 443.559
• Purity: ≥95%
• Target: EGFR inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• SMILES: CN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CN=C5)N(C(C)C)C4=N3)C=C2)CC1

SKLB-1028(CAT: I009514) is a novel oral multikinase inhibitor targeting epidermal growth factor receptor (EGFR), Fms-like tyrosine kinase 3 (FLT3), and Abelson tyrosine kinase (Abl). Its exceptional activity in models of FLT3-driven acute myeloid leukemia (AML) highlights its potential as a therapeutic agent for this aggressive malignancy. Additionally, SKLB-1028 demonstrates considerable potency in models of chronic myeloid leukemia (CML) with Abl mutants, suggesting its relevance in combating resistant forms of the disease.

Reference

1:Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26(8):1892-5. doi: 10.1038/leu.2012.67. Epub 2012 Mar 9. PubMed PMID: 22402607.